M14-360
A Phase 1 Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer (NSCLC)

Key Inclusion Criteria
• Participants with Histologically or cytologically confirmed Stage III non-small cell lung cancer (NSCLC) that is measurable
• Participants must have V20 (volume of lung to receive 20 Gy radiotherapy according to simulation) < 35%
• Participant must have an Eastern Cooperative Oncology Group (ECOG) performance score of 0 – 1
• Participant must have adequate hematologic, renal, hepatic, and lung function

Key Exclusion Criteria
• Participants with prior chemotherapy or radiotherapy (RT) for current NSCLC. Participants curatively treated for past early stage NSCLC greater than 3 years ago may be included.
• Participants with prior exposure to poly-ADP-ribose polymerase (PARP) inhibitors
• Participants with known hypersensitivity to carboplatin, paclitaxel, or formulations containing polyethoxylated castor oil (Cremophor).
• Participants with prior mediastinal or thoracic radiotherapy. Prior tangential RT to prior breast cancer is acceptable

Outcome Measures
Primary
• Progression-free survival (PFS)
Secondary
• Duration of Overall Response (DOR)
• Objective Response Rate (ORR)
• Overall Survival (OS)

Phase 1 / 2 current plan:
Veliparib with RT and Platinum for Locally Advanced NSCLC (M14-360)

Veliparib is an investigational drug which has not been approved by regulatory health agencies.
Efficacy and safety have not been established.
To learn more about our pipeline, please visit www.abbviescience.com/oncology

To learn more about these studies, please visit https://ClinicalTrials.gov or email abbbviclinicaltrials@abbvie.com